Literature DB >> 1355660

Mdr1/P-glycoprotein, topoisomerase, and glutathione-S-transferase pi gene expression in primary and relapsed state adult and childhood leukaemias.

V Gekeler1, G Frese, A Noller, R Handgretinger, A Wilisch, H Schmidt, C P Muller, R Dopfer, T Klingebiel, H Diddens.   

Abstract

In a variety of adult and childhood leukaemia cell samples collected at different states of the disease, we analysed in a series of sequentially performed slot-blot or Northern-blot hybridisation experiments the expression of genes possibly involved in multiple drug resistance (MDR) (mdr1/P-glycoprotein, DNA topoisomerase II, glutathione-S-transferase pi), and the expression of the DNA topoisomerase I and histone 3.1 genes. Occasionally, P-glycoprotein gene expression was additionally examined by indirect immunocytofluorescence using the monoclonal antibody C219. No significant difference in mdr1/P-glycoprotein mRNA levels between primary and relapsed state acute lymphocytic leukaemias (ALL) was seen on average. Second or third relapses, however, showed a distinct tendency to an elevated expression of this multidrug transporter gene (up to 10-fold) in part well beyond the value seen in the moderately cross-resistant T-lymphoblastoid CCRF-CEM subline CCRF VCR 100. Increased mdr1/P-glycoprotein mRNA levels were also found in relapsed state acute myelogenous leukaemias (AML), and in chronic lymphocytic leukaemias (CLL) treated with chlorambucil and/or prednisone for several years. Topoisomerase I and topoisomerase II mRNA levels were found to be very variable. Whereas in all but one case of CLL topoisomerase II mRNA was not detected by slot-blot hybridizations, strong topoisomerase I and topoisomerase II gene expression levels, frequently exceeding the levels monitored in the CCRF-CEM cell line, were seen in many cell samples of acute leukaemia. If topoisomerase II mRNA was undetectable, expression of topoisomerase I was clearly visible throughout. These observations might be valuable considering the possible treatment with specific topoisomerase I or topoisomerase II inhibitors. Significant positive correlations were found (i) for topoisomerase I and histone 3.1 gene expression levels in general (P less than 0.001), and (ii) in the CLL samples additionally for the expression levels of the mdr1 gene, and the histone 3.1, topoisomerase I, and glutathione-S-transferase pi genes, respectively.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1355660      PMCID: PMC1977945          DOI: 10.1038/bjc.1992.304

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  55 in total

1.  Some monoclonal antibody reagents (C219 and JSB-1) to P-glycoprotein contain antibodies to blood group A carbohydrate determinants: a problem of quality control for immunohistochemical analysis.

Authors:  C L Finstad; B W Yin; C M Gordon; M G Federici; S Welt; K O Lloyd
Journal:  J Histochem Cytochem       Date:  1991-12       Impact factor: 2.479

2.  Failure to detect the P-glycoprotein multidrug resistant phenotype in cases of resistant childhood acute lymphocytic leukaemia.

Authors:  P Ubezio; M Limonta; M D'Incalci; G Damia; G Masera; G Giudici; J S Wolverton; W T Beck
Journal:  Eur J Cancer Clin Oncol       Date:  1989-12

3.  Camptothecin overcomes MDR1-mediated resistance in human KB carcinoma cells.

Authors:  A Y Chen; C Yu; M Potmesil; M E Wall; M C Wani; L F Liu
Journal:  Cancer Res       Date:  1991-11-15       Impact factor: 12.701

4.  Characterization of the human MDR3 P-glycoprotein and its recognition by P-glycoprotein-specific monoclonal antibodies.

Authors:  A H Schinkel; E M Roelofs; P Borst
Journal:  Cancer Res       Date:  1991-05-15       Impact factor: 12.701

5.  Is the mdr 1 gene relevant in chronic lymphocytic leukemia?

Authors:  J A Holmes; A Jacobs; G Carter; J A Whittaker; D P Bentley; R A Padua
Journal:  Leukemia       Date:  1990-03       Impact factor: 11.528

6.  Coinduction of MDR-1 multidrug-resistance and cytochrome P-450 genes in rat liver by xenobiotics.

Authors:  R K Burt; S S Thorgeirsson
Journal:  J Natl Cancer Inst       Date:  1988-11-02       Impact factor: 13.506

7.  Overexpression of human topoisomerase I in baby hamster kidney cells: hypersensitivity of clonal isolates to camptothecin.

Authors:  K R Madden; J J Champoux
Journal:  Cancer Res       Date:  1992-02-01       Impact factor: 12.701

8.  Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells.

Authors:  C J Chen; J E Chin; K Ueda; D P Clark; I Pastan; M M Gottesman; I B Roninson
Journal:  Cell       Date:  1986-11-07       Impact factor: 41.582

9.  Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease.

Authors:  J M Chirgwin; A E Przybyla; R J MacDonald; W J Rutter
Journal:  Biochemistry       Date:  1979-11-27       Impact factor: 3.162

10.  Observations on the transcriptional activity of the glutathione S-transferase pi gene in human haematological malignancies and in the peripheral leucocytes of cancer patients under chemotherapy.

Authors:  S McQuaid; S McCann; P Daly; E Lawlor; P Humphries
Journal:  Br J Cancer       Date:  1989-04       Impact factor: 7.640

View more
  11 in total

1.  The clinical relevance and prognostic significance of adenosine triphosphate ATP-binding cassette (ABCB5) and multidrug resistance (MDR1) genes expression in acute leukemia: an Egyptian study.

Authors:  Hala M Farawela; Mervat M Khorshied; Neemat M Kassem; Heba A Kassem; Hamdy M Zawam
Journal:  J Cancer Res Clin Oncol       Date:  2014-05-08       Impact factor: 4.553

Review 2.  P-glycoprotein-mediated multidrug resistance in normal and neoplastic hematopoietic cells.

Authors:  T Licht; I Pastan; M Gottesman; F Herrmann
Journal:  Ann Hematol       Date:  1994-10       Impact factor: 3.673

Review 3.  Glutathione-related enzymes, glutathione and multidrug resistance.

Authors:  J A Moscow; K H Dixon
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

4.  Drug-induced changes in the expression of MDR-associated genes: investigations on cultured cell lines and chemotherapeutically treated leukemias.

Authors:  V Gekeler; J Beck; A Noller; A Wilisch; G Frese; M Neumann; R Handgretinger; G Ehninger; H Probst; D Niethammer
Journal:  Ann Hematol       Date:  1994       Impact factor: 3.673

5.  Differential expression of the topoisomerase II alpha and beta genes in human breast cancers.

Authors:  M I Sandri; D Hochhauser; P Ayton; R C Camplejohn; R Whitehouse; H Turley; K Gatter; I D Hickson; A L Harris
Journal:  Br J Cancer       Date:  1996-06       Impact factor: 7.640

6.  DNA topoisomerase IIalpha and -beta expression in human ovarian cancer.

Authors:  S Withoff; A G van der Zee; S de Jong; H Hollema; E F Smit; N H Mulder; E G de Vries
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

7.  Anticancer drug-mediated induction of multidrug resistance-associated genes and protein kinase C isozymes in the T-lymphoblastoid cell line CCRF-CEM and in blasts from patients with acute lymphoblastic leukemias.

Authors:  J F Beck; D Brügger; K Brischwein; C Liu; P Bader; D Niethammer; V Gekeler
Journal:  Jpn J Cancer Res       Date:  2001-08

8.  Evaluation of the Hypoglycemic Activity of Morchella conica by Targeting Protein Tyrosine Phosphatase 1B.

Authors:  Naeema Begum; Abdul Nasir; Zahida Parveen; Taj Muhammad; Asma Ahmed; Saira Farman; Nargis Jamila; Mohib Shah; Noor Shad Bibi; Akif Khurshid; Zille Huma; Atif Ali Khan Khalil; Ashraf Albrakati; Gaber El-Saber Batiha
Journal:  Front Pharmacol       Date:  2021-05-14       Impact factor: 5.810

9.  In vitro anthracycline cross-resistance pattern in childhood acute lymphoblastic leukaemia.

Authors:  E Klumper; R Pieters; M L den Boer; D R Huismans; A H Loonen; A J Veerman
Journal:  Br J Cancer       Date:  1995-06       Impact factor: 7.640

10.  P-glycoprotein and glutathione S-transferase pi in childhood acute lymphoblastic leukaemia.

Authors:  A Sauerbrey; F Zintl; M Volm
Journal:  Br J Cancer       Date:  1994-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.